Hematopoietic stem cell–driven anti-tumor immunity in bladder cancer
Official title: Hematopoietic stem cell encoded anti-tumor immunity: mechanisms and function
Funded at Sloan-Kettering Inst Can Research · NIH-11447641 · Data updated 2026-11-12
This grant explores how a bladder cancer therapy called BCG helps the immune system fight cancer, with a focus on patient-specific immune responses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 1, 2026 |
| Project end | June 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $745,471 |
| NIH project number | 1R01CA303125-01A1 |
| Project ID | NIH-11447641 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with non–muscle invasive bladder cancer who are treated with BCG and whose disease status is being evaluated.
✕Less likely to help
Patients not undergoing BCG therapy or with advanced disease not targeted by this mechanism-focused research may see limited direct benefit.
What this research studies
The project looks at how BCG, a bacterial therapy for bladder cancer, triggers long-lasting T cell immunity against tumor cells. It studies the early events in bone marrow stem cells that shape how immune cells respond later, potentially influencing treatment outcomes. By understanding these mechanisms, researchers hope to identify why some patients relapse and how to improve responses. The work combines animal models and human samples to connect basic science with potential clinical implications for bladder cancer care.
Why it matters
Potential benefit: If successful, the research could lead to better predictors of who will respond to BCG and new strategies to enhance its effectiveness for bladder cancer patients.
How similar studies have gone: Previous work suggests BCG induces tumor-specific immunity; this project aims to translate those mechanisms to improved patient outcomes, building on established but incomplete knowledge.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Glickman, Michael S — Sloan-Kettering Inst Can Research
- Study coordinator: Glickman, Michael S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.